USD 2.65 billion
Report ID:
SQMIG35J2031 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|Tables:
141
|Figures:
77
Hereditary Angioedema Treatment Market size was valued at USD 2.72 Billion in 2023 and is poised to grow from USD 2.79 Billion in 2024 to USD 10.66 Billion by 2032, growing at a CAGR of 2.56% during the forecast period (2025-2032).
The key factor driving market expansion is the increased acknowledgment of treating rare disorders such as hereditary angioedema (HAE). According to the National Organization for Rare Disorders (NORD), the scenario is estimated to affect around 1 in 50,000 persons, with this illness affecting 1 in 150,000 people worldwide. Angioedema attacks are characterised by abrupt, often severe swelling in several areas of the body, including the abdomen, limbs, throat, and face. Many organisations are raising awareness about the diseases and their treatments, such as the US Hereditary Angioedema Association, a non-profit organisation dedicated to providing HAE sufferers with access to cutting-edge remedy alternatives and dependable, private help to deal with symptoms.
According to a survey done in the United States, physicians indicated improvements in HAE care in recent years, according to the study. Due to recent therapeutic improvements, documented cases of HAE have improved, reducing anxiety about adverse treatment effects, and high levels of patient satisfaction have been noted. According to a July 2020 paper titled 'Spectrum of diagnosis of hereditary angioedema: Seven case reports,' roughly 30,000-50,000 persons in India are affected. Dermatologists, gastroenterologists, and clinical allergists handle the majority of cases.
US Hereditary Angioedema Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 2.65 billion
Largest Segment
Intravenous
Fastest Growth
Intravenous
Growth Rate
2.56% CAGR
To get more reports on the above market click here to Buy The Report
Hereditary Angioedema Treatment Market is segmented based on drug class, treatment type, route of administration, distribution channel, application, and region. Based on drug class, the Hereditary Angioedema Treatment Market is segmented into C1-esterase inhibitor, Brandykinin B2 receptor antagonist, Kallikrein inhibitor, others. Based on treatment, the Hereditary Angioedema Treatment Market is divided into prophylaxis, on demand. Based on route of administration, the Hereditary Angioedema Treatment Market is segmented into Intravenous, subcutaneous, oral. Based on distribution channel, the Hereditary Angioedema Treatment Market is segmented into hospital pharmacy, retail pharmacy. Based on application, the Hereditary Angioedema Treatment Market is segmented into Prophylaxis and treatment. Based on region, the market is segmented into North America, Asia Pacific, Europe, Latin America, and MEA.
Hereditary Angioedema Treatment Market Analysis by Drug Class:
The market is divided into C1-esterase inhibitors, Kallikrein inhibitors, B2 bradykinin receptor antagonists, and additional medications such as attenuated androgens and tranexamic acid based on drug class. C1-esterase inhibitors were the most profitable sector. The products' dominance in the market is related to their use in both on-demand and preventative treatment of HAE.
Hereditary Angioedema Treatment Market Analysis by Route of Administration:
The hereditary angioedema treatment market has been segmented into intravenous, subcutaneous, and oral administration routes. In terms of revenue, the intravenous treatments segment led the market. Existing therapies for HAE management are mostly administered intravenously, which has contributed significantly to its growth.
Intravenously administered therapies have long been the mainstay of treating patients with hereditary angioedema. Patients, on the other hand, have limited vascular access, restricting the administration of recurrent IV medicines. Other dangers linked with the implantation of long-term catheters for therapy include thrombosis and infection. Furthermore, patients face difficulties when receiving intravenous medicines on a regular basis, lowering treatment compliance.
To get detailed analysis on other segments, Request For Free Sample Report
North America dominated the global hereditary angioedema therapy market in 2021 and is expected to continue to do so during the forecast period. The high prevalence of hereditary angioedema, substantially better reported disease ratios, high healthcare expenditure, and availability of speciality HAE products are the primary drivers for the growth of the North American hereditary angioedema treatment market.
Due to increased patient awareness, Asia-Pacific is expected to dominate the global market. The rest of the world is expected to be a highly profitable in the market during the forecast period, owing to factors such as an increase in the number of reported cases of hereditary angioedema in recent times, increased awareness of rare diseases in developing countries, and the introduction of novel therapies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Hereditary Angioedema Treatment Market Drivers
Increased Emphasis on Advanced Therapeutics
Hereditary Angioedema Treatment Market Restraint
Request Free Customization of this report to help us to meet your business objectives.
The global hereditary angioedema treatment market is fragmented, with a prominent market player acquiring a sizable portion. Some of the market's leading companies such as Takeda Pharmaceutical Company Limited, CSL Limited, BIOCRYST PHARMACEUTICALS, INC., Pharming Group N.V., Ionis Pharmaceuticals, Novartis AG, CENTOGENE AG, Sanofi, KalVista Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., AstraZeneca, Medtronic are forming multiple strategic alliances in order to increase their market share and get a competitive edge.
Top Players in the Global Hereditary Angioedema Treatment Market
Hereditary Angioedema Treatment Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.
According to our market analysis, the global hereditary angioedema treatment market is expected to expand at a healthy rate during the projected period, owing to growing awareness and diagnosis of uncommon genetic illnesses, as well as product innovation for their treatment. Subcutaneous injections are becoming more popular due to patient convenience and ease, which has been aided by the introduction of innovative new products that use this route of administration. Due to the enormous number of reported cases and a well-established healthcare infrastructure, the North American regional market is likely to grow rapidly. Manufacturers concentrating on improving their product offerings and include tailored and specialty medications for the treatment of hereditary angioedema.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 2.65 billion |
Market size value in 2031 | USD 10.39 billion |
Growth Rate | 2.56% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
Historical Year | 2019 |
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Hereditary Angioedema Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Hereditary Angioedema Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Hereditary Angioedema Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Hereditary Angioedema Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Hereditary Angioedema Treatment Market size was valued at USD 2.65 billion in 2019 and is poised to grow from USD 2.72 billion in 2023 to USD 10.39 billion by 2031, growing at a CAGR of 2.56% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35J2031
sales@skyquestt.com
USA +1 351-333-4748